- Home
- AMGN vs TD Comparison
AMGN vs TD Comparison
Compare AMGN & TD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- TD
- Stock Information
- Founded
- AMGN 1980
- TD 1855
- Country
- AMGN United States
- TD Canada
- Employees
- AMGN N/A
- TD N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- TD
- Sector
- AMGN Health Care
- TD
- Exchange
- AMGN Nasdaq
- TD Nasdaq
- Market Cap
- AMGN 157.5B
- TD 126.6B
- IPO Year
- AMGN N/A
- TD N/A
- Fundamental
- Price
- AMGN $287.75
- TD $73.32
- Analyst Decision
- AMGN Hold
- TD Buy
- Analyst Count
- AMGN 20
- TD 2
- Target Price
- AMGN $321.65
- TD $91.50
- AVG Volume (30 Days)
- AMGN 2.0M
- TD 1.8M
- Earning Date
- AMGN 08-05-2025
- TD 08-28-2025
- Dividend Yield
- AMGN 3.34%
- TD 4.09%
- EPS Growth
- AMGN 110.88
- TD 63.11
- EPS
- AMGN 12.23
- TD 6.97
- Revenue
- AMGN $34,917,000,000.00
- TD $45,024,677,580.00
- Revenue This Year
- AMGN $7.96
- TD $10.95
- Revenue Next Year
- AMGN $1.70
- TD $3.82
- P/E Ratio
- AMGN $23.28
- TD $10.46
- Revenue Growth
- AMGN 12.88
- TD 20.69
- 52 Week Low
- AMGN $253.30
- TD $51.25
- 52 Week High
- AMGN $339.17
- TD $75.58
- Technical
- Relative Strength Index (RSI)
- AMGN 39.44
- TD 49.13
- Support Level
- AMGN $281.65
- TD $72.67
- Resistance Level
- AMGN $302.33
- TD $73.80
- Average True Range (ATR)
- AMGN 6.81
- TD 0.76
- MACD
- AMGN -2.59
- TD -0.28
- Stochastic Oscillator
- AMGN 9.48
- TD 26.41
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 55% of its revenue from Canada and has dominant market share in nearly all banking products and services. TD has around 40% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.